S

Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581

Watchlist Manager
Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581
Watchlist
Price: 10.64 CNY -1.39% Market Closed
Market Cap: 7B CNY
Have any thoughts about
Shandong Sinobioway Biomedicine Co Ltd?
Write Note

Shandong Sinobioway Biomedicine Co Ltd
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shandong Sinobioway Biomedicine Co Ltd
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
S
Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581
Accounts Payable
ÂĄ35.1m
CAGR 3-Years
32%
CAGR 5-Years
-8%
CAGR 10-Years
7%
Fufeng Group Ltd
HKEX:546
Accounts Payable
ÂĄ1.5B
CAGR 3-Years
-1%
CAGR 5-Years
4%
CAGR 10-Years
N/A
G
GHW International
HKEX:9933
Accounts Payable
ÂĄ275m
CAGR 3-Years
19%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Ningxia Baofeng Energy Group Co Ltd
SSE:600989
Accounts Payable
ÂĄ1.1B
CAGR 3-Years
28%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Zhejiang XinAn Chemical Industrial Group Co Ltd
SSE:600596
Accounts Payable
ÂĄ3B
CAGR 3-Years
16%
CAGR 5-Years
19%
CAGR 10-Years
13%
A
Anhui Jinhe Industrial Co Ltd
SZSE:002597
Accounts Payable
ÂĄ663.4m
CAGR 3-Years
14%
CAGR 5-Years
16%
CAGR 10-Years
8%
No Stocks Found

Shandong Sinobioway Biomedicine Co Ltd
Glance View

Market Cap
7B CNY
Industry
Chemicals

In the bustling world of biotechnology, Shandong Sinobioway Biomedicine Co Ltd stands as a dynamic player, deeply embedded in the heart of China's burgeoning pharmaceutical and biotech sector. Founded with a vision to harness the power of biology for transformative impacts, the company has charted a remarkable journey rooted in innovation and robust research capabilities. Sinobioway primarily delves into the development and commercialization of biological products, focusing on vaccines, antibodies, and other biopharmaceuticals. By emphasizing advanced biotechnologies, the company creates life-enhancing solutions, addressing both common and complex health challenges. Its strategic approach involves a blend of cutting-edge research, partnerships with academic institutions, and collaborations with global pharmaceutical giants, paving the way for market-leading products. Revenue streams for Sinobioway are predominantly driven by its diverse product portfolio that caters to a wide array of medical needs. Through comprehensive R&D, they've effectively commandeered a niche within the preventive medicine sector, particularly with their vaccines, which are in high demand due to increasing health awareness and governmental health initiatives. Additionally, the company fortifies its financial foundation through licensing deals, tapping into global markets and establishing a significant presence internationally. By strategically optimizing production processes and deploying an efficient distribution network, Sinobioway ensures its biomedicine products reach various demographics, thereby anchoring its position in the bioscience industry while continually seeking growth and expansion opportunities beyond local confines.

Intrinsic Value
3.06 CNY
Overvaluation 71%
Intrinsic Value
Price
S

See Also

What is Shandong Sinobioway Biomedicine Co Ltd's Accounts Payable?
Accounts Payable
35.1m CNY

Based on the financial report for Jun 30, 2024, Shandong Sinobioway Biomedicine Co Ltd's Accounts Payable amounts to 35.1m CNY.

What is Shandong Sinobioway Biomedicine Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
7%

Over the last year, the Accounts Payable growth was -25%. The average annual Accounts Payable growth rates for Shandong Sinobioway Biomedicine Co Ltd have been 32% over the past three years , -8% over the past five years , and 7% over the past ten years .

Back to Top